Pharmafile Logo

eliglustat

Genzyme enters $22.5m RNAi deal with Alnylam in Asia

Programme targets condition affecting heart and nervous system

- PMLiVE

FDA panel backs Sanofi’s Kynamro for high cholesterol

Recommendation comes despite safety concerns

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links